AR057793A1 - Derivado de colestanol, una formulacion liposomal y un complejo de inclusion de ciclodextrina que lo contienen y el uso del mismo en la produccion de un agente anticancer - Google Patents

Derivado de colestanol, una formulacion liposomal y un complejo de inclusion de ciclodextrina que lo contienen y el uso del mismo en la produccion de un agente anticancer

Info

Publication number
AR057793A1
AR057793A1 ARP060103846A ARP060103846A AR057793A1 AR 057793 A1 AR057793 A1 AR 057793A1 AR P060103846 A ARP060103846 A AR P060103846A AR P060103846 A ARP060103846 A AR P060103846A AR 057793 A1 AR057793 A1 AR 057793A1
Authority
AR
Argentina
Prior art keywords
agent
inclusion complex
colestanol
complex containing
derived
Prior art date
Application number
ARP060103846A
Other languages
English (en)
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR057793A1 publication Critical patent/AR057793A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Un compuesto azucar-colestanol que se puede sintetizar con facilidad, y que exhibe una actividad antitumoral satisfactoria. Un agente anticáncer que contiene, como ingrediente activo, un compuesto colestanol representado por la siguiente formula (1), o un complejo de inclusion de ciclodextrina que contiene el compuesto.
ARP060103846A 2005-09-02 2006-09-01 Derivado de colestanol, una formulacion liposomal y un complejo de inclusion de ciclodextrina que lo contienen y el uso del mismo en la produccion de un agente anticancer AR057793A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005255517 2005-09-02

Publications (1)

Publication Number Publication Date
AR057793A1 true AR057793A1 (es) 2007-12-19

Family

ID=37808952

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103846A AR057793A1 (es) 2005-09-02 2006-09-01 Derivado de colestanol, una formulacion liposomal y un complejo de inclusion de ciclodextrina que lo contienen y el uso del mismo en la produccion de un agente anticancer

Country Status (24)

Country Link
US (1) US7968116B2 (es)
EP (1) EP1921086B1 (es)
JP (1) JP5011113B2 (es)
KR (1) KR101292539B1 (es)
CN (1) CN101253192B (es)
AR (1) AR057793A1 (es)
AU (1) AU2006285678B2 (es)
BR (1) BRPI0615196A2 (es)
CA (1) CA2621377C (es)
CY (1) CY1115196T1 (es)
DK (1) DK1921086T3 (es)
ES (1) ES2459767T3 (es)
HK (1) HK1115140A1 (es)
HR (1) HRP20140439T1 (es)
IL (1) IL189752A (es)
MY (1) MY155903A (es)
NO (1) NO20081125L (es)
PL (1) PL1921086T3 (es)
PT (1) PT1921086E (es)
RU (1) RU2410389C2 (es)
SI (1) SI1921086T1 (es)
TW (1) TWI373473B (es)
WO (1) WO2007026869A1 (es)
ZA (1) ZA200802813B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ300722B6 (cs) * 2006-09-27 2009-07-22 Univerzita Karlova v Praze, Prírodovedecká fakulta Zpusob prípravy inkluzního komplexu pentacyklických a tetracyklických terpenoidu a farmaceutického prostredku obsahujícího tento inkluzní komplex, inkluzní komplex pentacyklického nebo tetracyklického terpenoidu a farmaceutický prostredek obsahující
TWI492759B (zh) 2008-03-05 2015-07-21 Otsuka Pharma Co Ltd 膽甾烷醇衍生物之併用用途
KR20110122682A (ko) * 2009-03-04 2011-11-10 오츠카 세이야쿠 가부시키가이샤 콜레스탄올 유도체의 병용 용도
JP5622719B2 (ja) * 2009-03-30 2014-11-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
PL2415470T3 (pl) 2009-03-30 2016-12-30 Kompozycja liposomowa
CA2865983C (en) 2012-03-02 2021-10-19 The Board Of Trustees Of The University Of Illinois Potent anticancer activity via dual compound activation
DK2822558T3 (da) 2012-03-06 2020-03-23 The Board Of Trustees Of The Univ Of Illionis Procaspase 3 aktivering ved hjælp af kombinations terapi
EP3290035B1 (en) 2012-03-06 2019-05-15 The Board of Trustees of the University of Illinois Procaspase combination therapy for treating cancer
CN103349948B (zh) * 2013-06-21 2015-05-27 江南大学 一种植物甾烷醇微胶囊化方法
RU2544455C1 (ru) * 2013-12-30 2015-03-20 Федеральное государственное бюджетное учреждение "Государственный научный центр колопроктологии" Министерства здравоохранения Российской Федерации Способ закрытой геморроидэктомии с гофрирующим швом
CN105753923B (zh) * 2014-12-17 2017-09-29 富力 20(R)‑人参皂苷Rg3多酰基化衍生物、制备及其应用
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
WO2019099873A1 (en) 2017-11-17 2019-05-23 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual mek signaling
US12090153B2 (en) 2018-10-05 2024-09-17 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS572300A (en) * 1980-06-09 1982-01-07 Tetsuo Suami Novel nitrosourea derivative
SE8902235D0 (sv) * 1989-06-20 1989-06-20 Haessle Ab Novel cyclodextrin inclusion complexes
JP4105258B2 (ja) * 1997-08-19 2008-06-25 大塚製薬株式会社 コレスタノール化合物及びこれを含有する医薬
JPH11160592A (ja) 1997-11-28 1999-06-18 Hitachi Cable Ltd 光ファイバケーブル用スペーサ
JP4351314B2 (ja) * 1998-12-24 2009-10-28 大塚製薬株式会社 コレスタノール化合物及びこれを含有する医薬
CN1822844B (zh) * 2003-07-17 2012-05-09 大塚制药株式会社 含配糖物的脂质体
CA2549074A1 (en) * 2003-12-18 2005-06-30 Unibioscreen S.A. Glycosylated steroid derivatives with anti-migratory activity
JP2005225822A (ja) * 2004-02-13 2005-08-25 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤
KR100603814B1 (ko) * 2004-03-11 2006-07-25 바이오스펙트럼 주식회사 나노리포좀 조성물

Also Published As

Publication number Publication date
HRP20140439T1 (hr) 2014-06-20
EP1921086A1 (en) 2008-05-14
CY1115196T1 (el) 2017-01-04
AU2006285678A1 (en) 2007-03-08
RU2410389C2 (ru) 2011-01-27
ES2459767T3 (es) 2014-05-12
TWI373473B (en) 2012-10-01
EP1921086B1 (en) 2014-04-16
EP1921086A4 (en) 2012-07-25
US20100292176A1 (en) 2010-11-18
CA2621377A1 (en) 2007-03-08
KR20080043838A (ko) 2008-05-19
JP5011113B2 (ja) 2012-08-29
PT1921086E (pt) 2014-04-29
NO20081125L (no) 2008-05-16
CA2621377C (en) 2013-10-22
MY155903A (en) 2015-12-15
CN101253192A (zh) 2008-08-27
SI1921086T1 (sl) 2014-05-30
KR101292539B1 (ko) 2013-08-20
JPWO2007026869A1 (ja) 2009-03-12
RU2008112676A (ru) 2009-10-10
HK1115140A1 (en) 2008-11-21
TW200738744A (en) 2007-10-16
PL1921086T3 (pl) 2014-09-30
US7968116B2 (en) 2011-06-28
ZA200802813B (en) 2009-10-28
WO2007026869A1 (ja) 2007-03-08
IL189752A (en) 2013-07-31
DK1921086T3 (da) 2014-05-05
BRPI0615196A2 (pt) 2011-05-10
AU2006285678B2 (en) 2012-01-19
CN101253192B (zh) 2011-05-04

Similar Documents

Publication Publication Date Title
AR057793A1 (es) Derivado de colestanol, una formulacion liposomal y un complejo de inclusion de ciclodextrina que lo contienen y el uso del mismo en la produccion de un agente anticancer
AR056751A1 (es) Composiciones pesticidamente activas que tienen actividad mejorada
BRPI0608291A2 (pt) agente imunossupressor e agente antitumoral que compreendem composto heterocìclico como ingrediente ativo
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
MX2007011048A (es) Composiciones estables de peroxido organico.
ZA200807274B (en) Novel pyridine derivatives
TW200700406A (en) Novel thiophene derivatives
TW200716591A (en) Novel thiophene derivatives
TW200716552A (en) Novel thiophene derivatives
TW200738670A (en) Novel thiophene derivatives
TW200730178A (en) Aerosol formulations for the inhalation of β-agonists
CL2008001721A1 (es) Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
WO2007005471A3 (en) Stable organic peroxide compositions
EA201170703A1 (ru) Производные адамантилбензамида
NO20073026L (no) 2-alkoksy-3,4,5-trihydroksy-alkylamider, fremstilling og sammensetninger derav samt anvendelse derav
TW200942524A (en) Novel aminomethyl benzene derivatives
TW200942530A (en) Pyridine compounds
MX2010009927A (es) Derivados de espiroindolinona.
MX2009011493A (es) Complejo de excipiente farmaceutico.
MX2019007633A (es) Composicion antitranspirante /desodorante.
WO2015003082A3 (en) Volatile organic compound formulations having antimicrobial activity
UA111324C2 (uk) Агент для профілактики або зменшення пігментації
NZ593169A (en) Anticancer compounds
TW200610526A (en) Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents

Legal Events

Date Code Title Description
FB Suspension of granting procedure